Menu
Subscribe - Individual
Subscribe - Biotech Premium (Corporate)
Home
About Us
Subscribe
Subscribe Individual
Subscribe Biotech Premium (Corporate)
Premium Biotech Coverage
Current News
Special Features
Company Index
Index Table
Summit
19th Bioshares Biotech Summit
Summit History
Contact
Contact Us
Email Alerts
Categories
Categories
Actinogen (ACW)
Adalta (1AD)
Amplia Therapeutics (ATX)
Anteris Technologies (AVR)
Aroa Biosurgery (ARX)
Blinklab (BB1)
Blog
Botanix (BOT)
Chimeric Therapeutics (CHM)
Clever Culture Systems (CC5)
Clinuvel Pharmaceuticals (CUV)
Cogstate (CGS)
Dimerix (DXB)
EBR Systems (EBR)
Immuron (IMC)
Imugene (IMU)
Island Pharmaceuticals (ILA)
Neuren Pharmaceuticals (NEU)
Patrys (PAB)
Syntara (SNT) (previously Pharmaxis, PXS)
Uncategorized
May 13th, 2025
Dimerix Stuns Market with Major US Licensing Deal
Read More
January 9th, 2025
Dimerix Secures Third Licensing Deal
Read More
December 5th, 2024
Dimerix: Unmet Need Drives Positive Changes to Trial Endpoints in FSGS
Read More
June 12th, 2024
Second Licensing Deal for Dimerix; Share Price Up 65%
Read More
January 4th, 2024
Top Six Picks for 2024 (Dimerix; ASX = DXB)
Read More
December 12th, 2023
Investor Interest Starts Return to Biotech Sector (Dimerix)
Read More
October 10th, 2023
Major Validation Deal for Dimerix
Read More
August 11th, 2023
Dimerix in Partnering Discussions, Interim Results out March 2024
Read More
May 19th, 2023
Dimerix to Raise $12 Million in Difficult Market
Read More
December 19th, 2022
Dimerix Completes Recruitment of First Stage in Phase III Study
Read More
October 18th, 2022
Dimerix – Recruitment Accelerating in Phase III Study
Read More
June 3rd, 2022
Dimerix - Structural Regulatory Changes in Kidney Diseases Perfect Timing
Read More
Pages
1
